FDA's eMDR program will soon be mandatory
This article was originally published in The Silver Sheet
Executive Summary
FDA is urging device manufacturers to begin using the agency's electronic Medical Device Reporting (eMDR) program in anticipation that they will be required to do so as early as next spring. Currently, the eMDR program - which aims to improve CDRH's ability to analyze adverse event reports so it can identify troubling patterns more efficiently - is voluntary ("The Silver Sheet" August 2007). However, that will change once the agency issues a final rule on the program early next year, Don St. Pierre, CDRH associate director for postmarket transformation, said Sept. 25 at the Regulatory Affairs Professionals Society (RAPS) annual conference in Boston. "You can do [electronic reporting] now or you can wait for it to be done to you," he said, noting that so far only 15 eMDRs have been filed with FDA, all by one company
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.